PURCHASE OF A XENOGEN'S IVIS IMAGING SYSTEM 200 WORKSTATION
购买 Xenogen 的 IVIS 成像系统 200 工作站
基本信息
- 批准号:7335169
- 负责人:
- 金额:$ 3.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-07-01 至 2007-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This subproject is one of many research subprojects utilizing the resources provided by a Shared Instrumentation Grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the grant, which is not necessarily the institution for the investigator. This Shared Instrumentation Grant application requests support to purchase a Xenogen biphotonic workstation for the imaging of whole, small animals. The instrument will be integrated into the existing Englert Image Analysis Facility, which is a shared resource of the Norris Cotton Cancer Center at Dartmouth Medical School. The workstation will provide new technologies to the community of NIH-funded scientists at Dartmouth College, the Thayer School of Engineering, Dartmouth Medical School and Dartmouth-Hitchcock Medical Center. As part of a comprehensive effort to expand whole animal imaging at Dartmouth, we propose the purchase of a Xenogen IVIS" Imaging System. This workstation will permit optical (fluorescence/bioluminescence) imaging of cells and biologicals in small animals and allow to image, in real time, the migration of cancer cells, the biodistribution of therapeutics, pharmacokinetic studies and studies of gene expression in situ. This new technology will allow Dartmouth, NIH-funded scientists to address specific questions that are heretofore unapproachable given existing, available technologies. In addition, because animals can be serially assessed for tumor growth or gene expression, this new technology will greatly reduce the number of animals needed for use in experimentation. The Englert Image Analysis Facility is an established shared resource supported by a number of institutional sources and is directed by a Director, co-director and an Advisory Board. There is extensive scientific and technical expertise at the faculty level for effective development of optical imaging technology. Faculty from the Thayer School of Engineering, who are experts in whole animal imaging and analysis will be an integral part of the development of this technology at Dartmouth. Long-term support and maintenance of the Xenogen workstation will be met by support from the NCI Core Grant to the Norris Cotton Cancer Center, together with users fees as well as institutional support from Dartmouth Medical School. Furthermore, Dartmouth Medical School has committed $50,000 towards the purchase of this instrument. The integration of this instrument will meet an important, needed component in the overall mission to build whole animal imaging technology at Dartmouth. We have identified 12 major and 2 minor users whose research capabilities will be markedly expanded given the availability of the Xenogen workstation. The role of this new technology to meet the needs of the NIH-sponsored specific aims for each of these research programs is presented.
该子项目是利用由NIH/NCRR资助的共享仪器赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得主要资金,因此可以在其他CRISP条目中表示。列出的机构是用于资助的,不一定是研究者的机构。此共享仪器补助金申请要求支持购买Xenogen双光子工作站,用于整个小动物的成像。该仪器将被集成到现有的恩格勒图像分析设施,这是一个共享资源的诺里斯棉花癌症中心在达特茅斯医学院。该工作站将为达特茅斯学院、塞耶工程学院、达特茅斯医学院和达特茅斯-希区柯克医学中心的NIH资助的科学家社区提供新技术。作为达特茅斯扩大整体动物成像的全面努力的一部分,我们建议购买Xenogen IVIS”成像系统。该工作站将允许对小动物的细胞和生物制剂进行光学(荧光/生物发光)成像,并允许对癌细胞的迁移、治疗剂的生物分布、药代动力学研究和原位基因表达研究进行真实的实时成像。这项新技术将允许达特茅斯,NIH资助的科学家解决特定的问题,迄今为止是无法接近现有的,可用的技术。此外,由于可以连续评估动物的肿瘤生长或基因表达,这项新技术将大大减少实验所需的动物数量。恩格勒特图像分析设施是一个既定的共享资源,得到一些机构来源的支持,并由一名主任、共同主任和一个咨询委员会领导。有广泛的科学和技术专业知识,在教师一级的光学成像技术的有效发展。来自塞耶工程学院的教师是整个动物成像和分析方面的专家,他们将成为达特茅斯这项技术发展的一个组成部分。Xenogen工作站的长期支持和维护将由NCI核心赠款向诺里斯棉花癌症中心提供支持,以及用户费用和达特茅斯医学院的机构支持。此外,达特茅斯医学院已承诺购买该仪器50 000美元。该仪器的集成将满足在达特茅斯建立整体动物成像技术的总体使命中的一个重要的、必要的组成部分。我们已经确定了12个主要用户和2个次要用户,由于Xenogen工作站的可用性,他们的研究能力将得到显着扩展。这种新技术的作用,以满足美国国立卫生研究院赞助的具体目标,这些研究计划的需求。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RANDOLPH J. NOELLE其他文献
RANDOLPH J. NOELLE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RANDOLPH J. NOELLE', 18)}}的其他基金
Targeting VISTA eradicates large, established PD-1/CTLA-4 resistant tumors
靶向 VISTA 根除大型、已确定的 PD-1/CTLA-4 耐药肿瘤
- 批准号:
10170281 - 财政年份:2017
- 资助金额:
$ 3.75万 - 项目类别:
Targeting VISTA eradicates large, established PD-1/CTLA-4 resistant tumors
靶向 VISTA 根除大型、已确定的 PD-1/CTLA-4 耐药肿瘤
- 批准号:
9917740 - 财政年份:2017
- 资助金额:
$ 3.75万 - 项目类别:
Retinoic acid in gut immune homestatis and infection
视黄酸在肠道免疫稳态和感染中的作用
- 批准号:
8913568 - 财政年份:2015
- 资助金额:
$ 3.75万 - 项目类别:
Retinoic acid in gut immune homestatis and infection
视黄酸在肠道免疫稳态和感染中的作用
- 批准号:
9205215 - 财政年份:2015
- 资助金额:
$ 3.75万 - 项目类别:
VISTA, a novel regulator of immunity and autoimmunity
VISTA,一种新型免疫和自身免疫调节剂
- 批准号:
8840881 - 财政年份:2012
- 资助金额:
$ 3.75万 - 项目类别:
VISTA, a novel regulator of immunity and autoimmunity
VISTA,一种新型免疫和自身免疫调节剂
- 批准号:
8463984 - 财政年份:2012
- 资助金额:
$ 3.75万 - 项目类别:
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease
负调节剂作为自身免疫性疾病新疗法的验证
- 批准号:
8314301 - 财政年份:2012
- 资助金额:
$ 3.75万 - 项目类别:
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease
负调节剂作为自身免疫性疾病新疗法的验证
- 批准号:
8461514 - 财政年份:2012
- 资助金额:
$ 3.75万 - 项目类别:
VISTA, a novel regulator of immunity and autoimmunity
VISTA,一种新型免疫和自身免疫调节剂
- 批准号:
8387505 - 财政年份:2012
- 资助金额:
$ 3.75万 - 项目类别:
Safe and effective anti CD154 antibodies for therapeutic intervention
用于治疗干预的安全有效的抗 CD154 抗体
- 批准号:
8523637 - 财政年份:2012
- 资助金额:
$ 3.75万 - 项目类别: